Registry series: Lung Cancer (adenocarcinoma)

Record number: 
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
Most recent risk assessment for Lung Cancer (Council of Europe, 2022): Any histotype of newly-diagnosed lung cancer is an unacceptable risk for organ donation. Lung cancer in the donor history: Treated lung cancer is considered to be associated with a high transmission risk. Risk may decrease after curative therapy, with recurrence-free time and with increasing probability of cure.
Time to detection: 
14 months
Alerting signals, symptoms, evidence of occurrence: 
Alerting signals not detailed. Patient developed a transmitted cancer in the heart allograft as well as distant metastases. The patient died 14 months without initiation of chemotherapy.
Demonstration of imputability or root cause: 
Assessment of disease transmission studied by biopsy confirmatory with comparison of the recipient cancer to the primary donor tumour or in some cases genetic allelic analysis (not specified in this particular case). It was noted in the report that the donor lung adenocarcinoma was missed during organ procurement, although this is not further specified.
Imputability grade: 
3 Definite/Certain/Proven
Groups audience: 
Suggest new keywords: 
heart transplant
registry series
Deceased donor
Lung cancer, type not specified
Suggest references: 
Expert comments for publication: 
The case is reported as part of a series from the Penn Tumor Registry.